AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
AI Drug Discovery’s Great Divide: Scale, Speed, and What Actually Works
The AI drug discovery market is increasingly split between companies building broad, platform-style systems and those focused on narrower, more experimentally grounded workflows. The debate is no longer whether AI belongs in drug discovery, but which operating model is most likely to produce real-world candidates and returns.
Pharmaceutical Executive: Lilly-Insilico Deal Shows AI Discovery Is Now a Licensing Business, Not Just a Platform Pitch
Pharmaceutical Executive’s report on the Lilly-Insilico agreement underscores a crucial market shift: AI drug discovery is increasingly monetized through research-and-licensing structures. That indicates buyers want product rights and development options, not just access to software or discovery services.
Reuters frames Lilly-Insilico agreement as evidence AI drug discovery is becoming a sourcing channel
Reuters reports that Eli Lilly has extended its partnership with Insilico Medicine for AI-powered drug discovery, reinforcing the idea that major drugmakers now view AI firms as external sources of pipeline opportunities. The significance lies in AI moving from service function to asset origination channel.
Eli Lilly’s reported $2 billion Insilico deal raises the stakes for AI drug development
Reuters reports Eli Lilly is set to sign a deal worth up to $2 billion with Insilico Medicine, a major signal that large pharma still sees strategic value in AI-native drug discovery platforms. The significance is less about headline size alone and more about what it says regarding confidence in externalized R&D models, especially when AI partners can offer speed, target selection, and chemistry capabilities in one package.
Drug Discovery AI Watchlist Suggests the Sector Is Entering a Sorting Phase
A new roundup of AI in drug discovery and development points to a field that is broadening, but also becoming more selective about what counts as meaningful progress. The emerging pattern is that partnerships, platform launches, and financings matter only when they show a tighter link between computation and experimental execution.
Genentech and NVIDIA Signal a New Phase in AI Drug Discovery: Infrastructure as Strategy
Genentech and NVIDIA have entered a strategic AI research collaboration aimed at accelerating drug discovery and development. The partnership underscores how leading biopharma companies increasingly view compute platforms, model architecture, and scientific data pipelines as strategic assets rather than commodity tools.
Two AI Drug-Design Startups Show the Field Is Competing on Toolchains, Not Just Models
A FirstWord Pharma look at two AI startups’ internal tooling highlights a maturing competitive landscape in which platform differentiation increasingly comes from integrated toolchains rather than single breakthrough models. For pharma buyers and investors, that is a useful signal that discovery AI is becoming an engineering discipline as much as a scientific one.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.